#ESC26: CRISPR Therapeutics to pursue highest dose of its lipid lowering gene editing therapy

MUNICH — CRISPR Therapeutics’ gene editing candidate showed mixed durability results a year after patients were dosed, according to early-stage data presented Friday at the annual meeting of the European Society of Cardiology. The company will ...